Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.01.031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025. Verfasst von Alhomidi Almotiri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra 15526, Saudi Arabia; European Cancer Stem …. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Genetic Therapy, Hematologic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shaqra University, Cardiff University, Saudi Arabian Cultural Bureau.
Abstract (Originalsprache)
In the setting of monogenic disease, advances made in genome editing technologies can, in principle, be deployed as a therapeutic strategy to precisely correct a specific gene mutation in an affected cell type and restore functionality. Using the β-hemoglobinopathies and hemophilia as exemplars, we review recent experimental breakthroughs using CRISPR-derived genome editing technology that have translated to significant improvements in the management of inherited hematologic disorders. Yet there are also challenges facing the use of CRISPR-mediated genome editing in these patients; we discuss possible ways to obviate those issues for furtherance of clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra 15526, Saudi Arabia; European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Ca…
- Department of Biological Sciences, Faculty of Science, National University of Singapore (NUS), Singapore 119077, Singapore.
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa 13133, Jordan; European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Car…
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa 13133, Jordan.
- European Cancer Stem Cell Research Institute, Cardiff University, School of Biosciences, Cardiff CF24 4HQ, UK. Electronic address: rodriguesn@cardiff.ac.uk.
Förderung
- Shaqra University
- Cardiff University
- Saudi Arabian Cultural Bureau
Zitieren
APA
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025). Treating genetic blood disorders in the era of CRISPR-mediated genome editing. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.01.031
Vancouver
Almotiri A, Abogosh A, Abdelfattah A, Alowaisy D, Rodrigues NP. Treating genetic blood disorders in the era of CRISPR-mediated genome editing. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.01.031
BibTeX
@article{Almotiri2025,
author = {Almotiri, Alhomidi and Abogosh, Ahmed and Abdelfattah, Ali and Alowaisy, Dalya and Rodrigues, Neil P},
title = {Treating genetic blood disorders in the era of CRISPR-mediated genome editing},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.01.031}
}
EUVIMED